Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 885-886, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhagat, C. I.
Right arrow Articles by Beilby, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhagat, C. I.
Right arrow Articles by Beilby, J. P.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2000;46:885-886.)
© 2000 American Association for Clinical Chemistry, Inc.

Letters

Plasma Ferritin in Acute Hepatocellular Damage

Chotoo I. Bhagata, Stephen Fletcher, John Joseph and John P. Beilby

Department of Clinical Biochemistry, PathCentre, Hospital Avenue, Nedlands 6009, Western Australia, Australia
a Author for correspondence. Fax 61-8-9346-3882; e-mail Chotoo.Bhagat@health.wa.gov.au.


To the Editor:

Plasma ferritin concentrations are increased in iron overload, liver diseases, infections, inflammatory conditions, and malignancy. Very high concentrations (>10 000 µg/L) have been described in Still disease (1) and less commonly in hemochromatosis. There are very few reports of ferritin concentrations in patients with acute hepatocellular damage (AHD). A review of extreme increases in ferritin found that liver disease was the cause of 20% of cases . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 Nephrol Dial TransplantHome page
M. M. Nascimento, M. E. Suliman, A. Bruchfeld, S. Y. Hayashi, R. C. Manfro, A. R. Qureshi, R. Pecoits-Filho, M. A. Pachaly, L. Renner, P. Stenvinkel, et al.
The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients
Nephrol. Dial. Transplant., December 1, 2004; 19(12): 3112 - 3116.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.